Discover and read the best of Twitter Threads about #PDL1
Most recents (5)
1) Welcome to a new #accredited #tweetorial, "Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC," featuring the highlights of a symposium presented at the #ESMOIO22 congress.
@myESMO #LCSM #FOAMed
@myESMO #LCSM #FOAMed
2) The faculty for this outstanding program were @peters_solange (Chair) 🇨🇭, @HosseinBorghaei 🇺🇸, Natasha Leighl MD 🇨🇦, and @dplanchard 🇫🇷. A truly international roster of experts in #oncology!
Don't miss prior accredited courses in this space at oncologytweetorials-ce.com/category/lung-….
Don't miss prior accredited courses in this space at oncologytweetorials-ce.com/category/lung-….
3) This program is supported by an educational grant from Sanofi. Statement of accreditation and author disclosures are at oncologytweetorials-ce.com/disclosures/.
Sponsored by @Roche,
I would like to share a Tweetorial about recent important advances in the management of advanced/metastatic triple negative breast cancer (mTNBC)
#Tweetorial #Oncology #Cancer #Diagnosis #TNBC #Immunotherapy #PDL1
I would like to share a Tweetorial about recent important advances in the management of advanced/metastatic triple negative breast cancer (mTNBC)
#Tweetorial #Oncology #Cancer #Diagnosis #TNBC #Immunotherapy #PDL1
TNBC is a challenging disease to treat due to its aggressive behavior, heterogeneity, and the lack of universal actionable targets. mTNBC is commonly diagnosed at a younger age than other BC subtypes and its prognosis is poor, with a median survival of <2 years.
Advanced TNBC can result from recurrence after treatment in the early-stage disease setting, or it may be diagnosed at initial (de novo) presentation
@myESMO #ESMO20 as a #trainee can be #overwhelming! So many good studies, some more #practicechanging then others, if you missed some and want to understand (albeit at a simplistic #trainee level), sit back, relax and enjoy as we go through some great data #ESMO20 @OncoAlert
1. #NSCLC: 2 major studies #ADAURA #CROWN for adjuvant #EGFRmNSCLC, and advanced #ALK+ experts can provide better perspective @JackWestMD @n8pennell @StephenVLiu @AMansfieldMD @CharuAggarwalMD @NarjustDumaMD @GlopesMd @DevikaDasMD @OncoAlert
1. A) #ADAURA: Stage IB-IIIA #resected #NSCLC with #EGFRm treated with #Osimertinib vs #placebo [SOC prior to this was adjuvant chemotherapy [cisplatin-based doublet based on #LACE metanalysis- pubmed.ncbi.nlm.nih.gov/18506026/] showed improvement in #DFS @NEJM nejm.org/doi/full/10.10…
#ASCO20 Very promising results from PrECOG 0505 trial presented by @FordePatrick: Single arm phase II of durvalumab with cis/pem as 1L treatment for unresectable pleural mesothelioma (#MPM) #OncoAlert
#ASCO20 PrE0505 enrolled 55 patients (75% epithelioid) in 1y and treated with 6 cycles of standard cis/pem with durva 1120mg q3w followed by durva maintenance therapy (until PD). #OncoAlert
#ASCO20 Impressive OS numbers here with addition of durvalumab to cis/pem in #MPM with median of 20.4m and a 1y OS rate of 70.4%. Median PFS was 6.7m and RR was 56% (in the Australian DREAM trial RR was 48%). #OncoAlert
1/
How about a #Tweetorial on immunotherapy in quiz and answer form? Let’s try it! I’ll post a quiz in one tweet and then the answer in the next, and so on. Scroll down to follow the thread!
#pathology #pulmpath #ihcpath #pdl1 #Immunotherapy #pathtweetorial
How about a #Tweetorial on immunotherapy in quiz and answer form? Let’s try it! I’ll post a quiz in one tweet and then the answer in the next, and so on. Scroll down to follow the thread!
#pathology #pulmpath #ihcpath #pdl1 #Immunotherapy #pathtweetorial
2/
First question. When PD-1 on T cells binds PD-L1 on tumor cells, what happens to the T cells?
First question. When PD-1 on T cells binds PD-L1 on tumor cells, what happens to the T cells?
3/
The correct answer is that the binding of PD-1 to PD-L1 INHIBITS T cell killing of tumor cells.
See nice tweet on this by @kis_lorand
The correct answer is that the binding of PD-1 to PD-L1 INHIBITS T cell killing of tumor cells.
See nice tweet on this by @kis_lorand
